A synthetic vaccine developer is using a $750,000 small business innovation research grant from the U.S. Department of Defense to test the safety of its electrical drug delivery method with its DNA vaccines to guard against bioterrorism, according to a company statement. The drug delivery system from Inovio Pharmaceuticals (NYSE AMEX:INO) uses an electrical charge […]
A synthetic vaccine developer has added a former Merck vaccines president to its board of directors. Dr. Adel A.F. Mahmoud joined the board of Inovio Pharmaceuticals (NYSE AMEX:INO) this week. He served as president of Merck Vaccines as well as Merck’s chief medical adviser for vaccines and infectious diseases for six years until 2005. For […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Inovio Pharmaceuticals (NYSE:INO) has closed a public offering in which it raised $4 million. It said in a statement that it will use the proceeds toward clinical trial and research and development expenses. Inovio Pharmaceuticals, a Blue Bell, Pennsylvania synthetic vaccine developer, has three drugs in phase 2 clinical trials for cervical cancer, HIV and […]